Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate

Figure 9

Percentage of patients with amenorrhoea and clinically significant reduction of the volume of the fibroids of ≥ 25% [10].